← Leaderboards
Wenwei Hu
Rutgers Biomedical And Health Sciences
$6,833,356
Attributed
$8,852,140
Total exposure
5
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.2M · FY2012–25$2M$1.5M$1M$500K$0
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$8,852,140 · 5
By mechanism
R01$8,852,140 · 5
Top collaborators
- Zhaohui Feng10 shared
Most similar at Rutgers Biomedical And Health Sciences
Same institution · by research overlap
- Nan Gao$7,332,534
- Steven W Levison$6,327,050
Others in their field
Top investigators on “Tumor”
- David Heimbrook · Leidos Biomedical Research, Inc.$636,492,067
- Leonard Freedman · Leidos Biomedical Research, Inc.$360,535,780
- Gregory H Reaman · National Childhood Cancer Foundation$208,276,509
- Richard K. Wilson · Washington University$203,917,615
- Norman Wolmark · Nsabp Foundation, Inc.$177,323,696
- Ronald T Mitsuyasu · University Of California Los Angeles$138,361,819
Research focus
TumorTumorigenesisPlayBaseTp53 GeneCancer CellMediatingTumor ProgressionTumor SuppressionSamplingMouse ModelColorectal NeoplasmsRegulationColorectal CancerLipidsMalignant NeoplasmsPathway InteractionsMolecularMetabolicKnock-In MouseMetabolismFeedbackDown-RegulationOverexpression
Grant awards (25)
Gain-of-function mutant p53 and metabolic reprogramming in colorectal cancer$459,611
R01 · FY2025 · CA · contact PI
The role of leukemia inhibitory factor in colorectal cancer$426,972
R01 · FY2025 · CA · contact PI
Gain-of-function mutant p53 and metabolic reprogramming in colorectal cancer$436,631
R01 · FY2024 · CA · contact PI
The role of leukemia inhibitory factor in colorectal cancer$222,737
R01 · FY2024 · CA · contact PI
Gain-of-function mutant p53 and metabolic reprogramming in colorectal cancer$450,420
R01 · FY2023 · CA · contact PI
The role of leukemia inhibitory factor in colorectal cancer$368,879
R01 · FY2023 · CA · contact PI
Gain-of-function mutant p53 and metabolic reprogramming in colorectal cancer$450,420
R01 · FY2022 · CA · contact PI
The role of leukemia inhibitory factor in colorectal cancer$372,497
R01 · FY2022 · CA · contact PI
Metabolic reprogramming in breast cancer$356,438
R01 · FY2022 · CA
Gain-of-function mutant p53 and metabolic reprogramming in colorectal cancer$440,108
R01 · FY2021 · CA · contact PI
Metabolic reprogramming in breast cancer$363,713
R01 · FY2021 · CA
The role of chronic stress in regulation of mutant p53 and tumorigenesis$363,306
R01 · FY2021 · CA · contact PI
Metabolic reprogramming in breast cancer$363,713
R01 · FY2020 · CA
The role of chronic stress in regulation of mutant p53 and tumorigenesis$363,306
R01 · FY2020 · CA · contact PI
Metabolic reprogramming in breast cancer$352,801
R01 · FY2019 · CA
The role of chronic stress in regulation of mutant p53 and tumorigenesis$352,406
R01 · FY2019 · CA · contact PI
Metabolic reprogramming in breast cancer$363,713
R01 · FY2018 · CA
The role of chronic stress in regulation of mutant p53 and tumorigenesis$363,306
R01 · FY2018 · CA · contact PI
The role of chronic stress in regulation of mutant p53 and tumorigenesis$363,306
R01 · FY2017 · CA · contact PI
The Role of LIF, a Novel Negative Regulator of p53, in Colorectal Cancer$291,169
R01 · FY2017 · CA · contact PI
The Role of LIF, a Novel Negative Regulator of p53, in Colorectal Cancer$291,169
R01 · FY2016 · CA · contact PI
The Role of LIF, a Novel Negative Regulator of p53, in Colorectal Cancer$291,169
R01 · FY2015 · CA · contact PI
The Role of LIF, a Novel Negative Regulator of p53, in Colorectal Cancer$106,370
R01 · FY2014 · CA · contact PI
The Role of LIF, a Novel Negative Regulator of p53, in Colorectal Cancer$310,130
R01 · FY2013 · CA · contact PI
The Role of LIF, a Novel Negative Regulator of p53, in Colorectal Cancer$327,850
R01 · FY2012 · CA · contact PI